Florian Gessler1, Joshua D Bernstock2, Anne Braczynski3, Stephanie Lescher4, Peter Baumgarten1,3, Patrick N Harter3, Michel Mittelbronn3, Tianxia Wu5, Volker Seifert1, Christian Senft1. 1. Department of Neurosurgery, University Hospital Frankfurt, Goethe-University, Frankfurt, Germany. 2. Stroke Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS/NIH), Bethesda, Maryland. 3. Neurological Institute (Edinger Institute), University Hospital Frankfurt, Goethe-University, Frankfurt, Germany. 4. Institute of Neuroradiology, University Hospital Frankfurt, Goethe-University, Frankfurt, Germany. 5. Clinical trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS/NIH), Bethesda, Maryland.
Abstract
BACKGROUND: Previous studies addressing the influence of surgery on the outcome of patients with glioblastomas (GBM) have not addressed molecular markers. The value of surgery versus the tumor's major biological markers remains unclear. OBJECTIVE: We investigate the extent of resection as a prognosticator for patients with newly diagnosed primary GBM with the incorporation of molecular diagnostics as per the updated WHO 2016 diagnostic criteria for GBM. METHODS: Patients with newly diagnosed GBM who underwent resection were prospectively included within a database. We analyzed patients with newly diagnosed GBM and excluded patients who presented with IDH1 R132H mutations. Gross total resection (GTR) was defined as complete removal of enhancing disease. RESULTS: One hundred seventy-five patients were included within the analysis. One hundred four patients (59.4%) had GTR, 71 patients (40.6%) had subtotal or partial resection. Eighty patients (45.7%) displayed O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, 95 patients (54.3%) showed no MGMT promoter methylation. In Cox regression analysis, MGMT promoter methylation (hazard ratio [HR] 1.55; 95% confidence interval [CI], 1.01-2.19; P = .0133) and GTR (HR 1.48; 95% CI, 1.06-2.07; P = .0206) were significantly associated with favorable progression-free survival. MGMT promoter methylation (HR 2.13; 95% CI, 1.45-3.12; P = .0001) and GTR (HR 1.81; 95% CI, 1.24-2.63; P = .002) were associated with favorable overall survival (OS). Of other risk factors analyzed, age (>60 vs ≤ 60 yr) was significantly associated with progression-free survival (HR 1.60; 95% CI, 1.14-2.24; P = .006) and OS (HR 2.19; 95% CI, 1.51-3.19; P < .0001). CONCLUSION: GTR and MGMT promoter methylation are independent prognosticators for improved overall and progression-free survival in a homogeneous cohort of newly diagnosed patients with IDH wild-type glioblastoma.
BACKGROUND: Previous studies addressing the influence of surgery on the outcome of patients with glioblastomas (GBM) have not addressed molecular markers. The value of surgery versus the tumor's major biological markers remains unclear. OBJECTIVE: We investigate the extent of resection as a prognosticator for patients with newly diagnosed primary GBM with the incorporation of molecular diagnostics as per the updated WHO 2016 diagnostic criteria for GBM. METHODS:Patients with newly diagnosed GBM who underwent resection were prospectively included within a database. We analyzed patients with newly diagnosed GBM and excluded patients who presented with IDH1R132H mutations. Gross total resection (GTR) was defined as complete removal of enhancing disease. RESULTS: One hundred seventy-five patients were included within the analysis. One hundred four patients (59.4%) had GTR, 71 patients (40.6%) had subtotal or partial resection. Eighty patients (45.7%) displayed O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, 95 patients (54.3%) showed no MGMT promoter methylation. In Cox regression analysis, MGMT promoter methylation (hazard ratio [HR] 1.55; 95% confidence interval [CI], 1.01-2.19; P = .0133) and GTR (HR 1.48; 95% CI, 1.06-2.07; P = .0206) were significantly associated with favorable progression-free survival. MGMT promoter methylation (HR 2.13; 95% CI, 1.45-3.12; P = .0001) and GTR (HR 1.81; 95% CI, 1.24-2.63; P = .002) were associated with favorable overall survival (OS). Of other risk factors analyzed, age (>60 vs ≤ 60 yr) was significantly associated with progression-free survival (HR 1.60; 95% CI, 1.14-2.24; P = .006) and OS (HR 2.19; 95% CI, 1.51-3.19; P < .0001). CONCLUSION:GTR and MGMT promoter methylation are independent prognosticators for improved overall and progression-free survival in a homogeneous cohort of newly diagnosed patients with IDH wild-type glioblastoma.
Authors: Pieter L Kubben; Alida A Postma; Alfons G H Kessels; Jacobus J van Overbeeke; Henk van Santbrink Journal: Neurosurgery Date: 2010-11 Impact factor: 4.654
Authors: M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245
Authors: Yoshikazu Okamoto; Pier-Luigi Di Patre; Christoph Burkhard; Sonja Horstmann; Benjamin Jourde; Michael Fahey; Danielle Schüler; Nicole M Probst-Hensch; M Gazi Yasargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki Journal: Acta Neuropathol Date: 2004-04-28 Impact factor: 17.088
Authors: Thierry Gorlia; Martin J van den Bent; Monika E Hegi; René O Mirimanoff; Michael Weller; J Gregory Cairncross; Elizabeth Eisenhauer; Karl Belanger; Alba A Brandes; Anouk Allgeier; Denis Lacombe; Roger Stupp Journal: Lancet Oncol Date: 2007-12-21 Impact factor: 41.316
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Adomas Bunevicius; Stylianos Pikis; Douglas Kondziolka; Dev N Patel; Kenneth Bernstein; Erik P Sulman; Cheng-Chia Lee; Huai-Che Yang; Violaine Delabar; David Mathieu; Christopher P Cifarelli; David E Arsanious; Basem A Dahshan; Joshua S Weir; Herwin Speckter; Angel Mota; Manjul Tripathi; Narendra Kumar; Ronald E Warnick; Selcuk Peker; Yavuz Samanci; Gene Barnett; Farid El Hefnawi; Ghusn Al Sideiri; Jason Sheehan Journal: J Neurooncol Date: 2021-11-19 Impact factor: 4.130
Authors: Fatih Incekara; Sebastian R van der Voort; Hendrikus J Dubbink; Peggy N Atmodimedjo; Rishi Nandoe Tewarie; Geert Lycklama; Arnaud J P E Vincent; Johan M Kros; Stefan Klein; Martin van den Bent; Marion Smits Journal: Front Oncol Date: 2020-05-12 Impact factor: 6.244
Authors: Patrick C Gedeon; Cosette D Champion; Kristen E Rhodin; Karolina Woroniecka; Hanna R Kemeny; Alexa N Bramall; Joshua D Bernstock; Bryan D Choi; John H Sampson Journal: Expert Rev Clin Pharmacol Date: 2020-09-11 Impact factor: 5.045
Authors: Fatih Incekara; Marion Smits; Linda Dirven; Eelke M Bos; Rutger K Balvers; Iain K Haitsma; Joost W Schouten; Arnaud J P E Vincent Journal: Front Oncol Date: 2021-05-19 Impact factor: 6.244